#AI #ML #NLP #drugdiscovery #antibodies 🧬+šŸ”®=šŸ’Š

London, England
Joined July 2009
New(ish) paper w/ @LabGenius: EVAā„¢, our closed-loop ML + high-throughput experimentation platform, engineers multispecific T-cell engagers with complete tumour-killing selectivity — addressing on-target, off-tumour toxicity in solid tumours. 🧬 tandfonline.com/doi/full/10.…
6
341
Wild how the @britishmuseum has completely fumbled a potentially stellar exhibition with greed and poor planning. I’m sure they will make a lot of money this year but their members will desert them for the next 5. Lifetime value of a committed member is Ā£1k-3k.
2
4
60
Was excited to try @AnthropicAI Claude 5.5 but getting bio hazard flags for just trying to refactor some very standard biotech code. 😭 Can we get white listed please @nc_frey ? We are trying to cure cancer using AI just like your boss keeps saying it will.
2
1
15
2,080
Justin Grace retweeted
ColabFold2 Sneak Peak - integrates: alphafold3, openfold3, intellifold2, protenix2, boltz2, opendde, rosettafold3, chai1, esmfold2, openbind0 (thx Julia Buhmann), fully in Jax! šŸ—’ļø Colab Notebook colab.research.google.com/gi… šŸ pip install gist.github.com/sokrypton/75… (2/3)
4
44
161
7,741
Justin Grace retweeted
We’re releasing torchX—an open-source framework for Predicting, Designing, and Scoring Biomolecular Interactions. 🧬 TorchFold improves antibody–antigen structure prediction through large-scale sequence-pair distillation (25K abag complexes from earlier TorchFold ckpts), reaching 70.1% top-ranked success on FoldBench-AB. Since TorchFold is a direct re-implementation of AF3, and you may also use our model weights from your built AF3 with comparable performance. šŸ› ļø TorchCraft turns a frozen all-atom structure predictor into a design engine for minibinders, VHHs, cyclic peptides and ligand-binding proteins—with experimentally validated minibinder and VHH designs. šŸ“Š TorchScore evaluates candidate complexes without regenerating their structures, using the same TorchFold model weights. GPU and Huawei Ascend NPU implementations, TorchFold training code, training data and antibody–antigen model weights are available under the MIT license. A huge thank-you to the team at Changping Laboratory. We’re excited to see what the community builds with torchX! Explore the papers, code, models and web server. Papers: torchx-cpl.github.io Code: github.com/Mingchenchen/Torc… Models: huggingface.co/datasets/Torc… Web server: torchfold.openi.org.cn/
1
9
1
72
7,004
The SEPIQ challenge has released a large dataset of +1.8 million VHH sequences to make progress on one of computational biology's toughest open problems. Join the challenge and help build the next generation of computational tools for predicting antibody–antigen interactions: huggingface.co/spaces/sepiq-…
only a few people seem to know about the incredibly rich data on antibodies for cancer that was released as part of the SEPIQ challenge absolute gold data that may have the answer to breast cancer in it
2
24
1
134
12,936
Justin Grace retweeted
Our group discovered that reasoning models produce fractals when asked to solve hard problems. We can use nonlinear dynamics to probe the thinking processes of recurrent depth models on Sudoku, mathematics, and even ARC-AGI (1/N) arxiv.org/abs/2609.04963
113
622
126
4,716
461,403
Typically I am excited to try new model releases but I’ve not bothered with fable 5.1 due to experiences with 5 and posts I’ve seen from bioml community. Would anyone doing protein engineering recommend it or is this a skip, just like 5.0? @AnthropicAI
2
136
A question that has bugged me for a long time around de novo is how does it translate into real therapeutics? Is the idea that in time it will work for antibodies or that in time mini proteins will be an accepted therapeutic format?
Replying to @jusjosgra
antibodies or miniproteins? the former yes, the latter no
1
1
176
I think I’m quite bearish on either of these coming true. Abs seems more likely but not without extensive in vitro optimisation. There is no evolutionary signal from protein data due to VDJ recombination
1
22
I have a de novo model that gets 10% hit rates and a downstream traditional in silico protein engineering pipeline that increases those hit rates to 20%. I train a single policy network using RL and recapitulate 20% hit rates. Have I made a meaningful contribution?
4
8
1,427
Additional detail — the RL model is trained on the data from the downstream pipeline only. Effectively it’s a distillation of the trad pipeline into a single policy network.
1
87
Also — this isn’t targeted at the Claude announcement, which this isn’t an analogy for, more a general hypothetical for ML in bio generally. If ML is information compression, is distilling traditional tools into a fancy looking model real progress?
74
Seeing lots of down playing of these results. To me it feels like an inherent bias towards ā€œonly new model architecturesā€ constitute progress. The real world outcome is what’s important, & this is more significant than triangle attention
Replying to @AnthropicAI
Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%. Between 22% and 35% of Claude's designs bound successfully, depending on the setup. Some of its strongest designs bound several times more tightly than the best published de novo binder.
126
Justin Grace retweeted
Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%. Between 22% and 35% of Claude's designs bound successfully, depending on the setup. Some of its strongest designs bound several times more tightly than the best published de novo binder.
53
64
35
1,281
314,953
1/ What could we discover if we had a binder for every protein in the human proteome? We are excited to introduce the Bindome, an open and free resource of over 300,000 designed protein binder candidates against over 8,000 human target proteins. 🧵
20
113
8
497
48,628
One fold. Many different jobs. Antibodies, T-cell receptors, MHC molecules, cell adhesion proteins, even a giant muscle protein like titin — all of them use the same ancient structural building block: a small β-sandwich domain called the immunoglobulin fold. It first showed up in evolution long before immune systems as we know them existed. Then, over hundreds of millions of years, it got duplicated, again and again, and each copy drifted off to do something completely different: → In antibodies, it became a shape-shifting recognition system that can bind virtually any molecule on Earth → In MHC proteins, it became the machinery that shows the immune system what's happening inside your cells → In NCAM and other adhesion molecules, it became the glue that lets neurons find each other and build the brain → In titin, it became a mechanical spring inside your muscles Same fold. Wildly different destinies. It's a striking reminder that evolution copies what already works, then lets each copy wander in a new direction. The immunoglobulin superfamily is one of the clearest examples of this principle in the entire genome, and it's a big part of why your immune system, your nervous system, and even your muscles all quietly speak a shared molecular dialect. What's your favorite example of one biological design being reused across wildly different systems?
3
17
1
76
6,341
Justin Grace retweeted
It’s getting hard to keep track of all the new open-source cofolding models coming out. To help everyone stay up to date, I'm excited to share cofoldarena.ai, a PDB-synced leaderboard of open models, updated weekly. All predictions are available to view & download! (1/4)
25
99
14
437
51,262
Justin Grace retweeted
This is very nice framing of a problem highly relevant to bioML folks. Relatedly, we wrote a simple recipe in 2023, with wet-lab validations (which has replicated many times since), that is designed to mitigate exposure bias in sequence design (in a related setting, but can be applied here too).
3
12
112
16,569
Antigen-specific Antibody Multi-modal Foundation Model for Functional Antibody Design 1 AAMFM is an antigen-specific antibody multimodal foundation model built on ESM3 that jointly models antibody sequence and structure while being explicitly conditioned on antigen context, aiming to close the gap where general protein language models struggle: epitope-level, paired antibody–antigen design. 2 The core idea is to put antibody sequence tokens, antibody structure tokens, and antigen-derived signals into a shared latent space, so generation is driven by the actual complex context (antigen geometry + epitope annotations), not just antibody priors. 3 A key engineering choice is a lightweight Antigen Geometric–Epitope-aware Adapter (about 5.1M params, ~0.36% of the 1.4B base model) inserted after the last attention block, enabling antigen conditioning without retraining the entire foundation model from scratch. 4 Antigen conditioning is multi-source: (a) antigen 3D geometry is encoded as a graph and embedded via GearNet to produce geometric features; (b) epitope sites are provided as a binary mask and encoded with embeddings + positional encoding + a Transformer encoder to capture interface context; (c) these signals are fused with the antibody backbone representation via down-projection/concat/MLP/up-projection with a residual update. 5 Training is hierarchical: (a) start from ESM3-open (1.4B); (b) antibody domain adaptation by continued pretraining on ~1.4M paired antibody sequence–structure examples from OAS (structures predicted by AbodyBuilder2/IgFold, with coordinate noise augmentation); (c) supervised fine-tuning on high-resolution SAbDab antibody–antigen complexes, learning more realistic interaction patterns. 6 The masking strategy is antibody-aware: besides random masking, they frequently mask entire CDR regions (and in SFT sometimes mask only within CDRs), forcing the model to learn CDR completion/design under fixed frameworks—aligned with how antibodies vary in nature and how design is practiced. 7 The functional alignment step is AF3-driven preference optimization: candidate CDR sequences sampled from the SFT model are evaluated by Protenix (an open AlphaFold3 reproduction) to obtain AF3 ranking score, pTM, and ipTM as structure-and-binding confidence signals; these scores are used as an oracle to define preferences for post-training. 8 To reduce ā€œreward hackingā€ against the structural oracle, preferences are constrained by a second, nearly orthogonal plausibility signal: AntiBERTy pseudo-log-likelihood (PLL). Preference pairs are kept only when the preferred sequence beats the rejected one by at least 0.2 AF3-score and 0.1 PLL (Spearman correlation between AF3-score and PLL reported as 0.13). 9 Preference learning uses Calibrated Direct Preference Optimization (Cal-DPO), optimizing only over CDR tokens (length-normalized). Compared to standard DPO, Cal-DPO adds a calibration term so likelihood ratios reflect absolute quality margins, empirically stabilizing training dynamics (preferred likelihood stays steadier while dispreferred decreases). 10 Results on SAbDab design benchmarks show consistent gains in plausibility and complex-level functional metrics: for full antibody (all 6 CDRs) co-design, AAMFM-CalDPO improves AF3-score, pTM, and ipTM over ESM3-open and antibody-specific baselines (DiffAb, dyMEAN, AbX). In epitope-binding CDR-H3 co-design, AAMFM variants lead on PLL and AF3-derived functional scores, with competitive AAR/RMSD tradeoffs typical of shifting from memorization (SFT) to preference-guided exploration (DPO). šŸ’»Code: github.com/XL-S224/AAMFM. šŸ“œPaper: arxiv.org/abs/2607.20057 #ComputationalBiology #ProteinDesign #AntibodyDesign #ProteinLanguageModels #MultimodalAI #AlphaFold3 #ESM3 #DPO #Bioinformatics #MachineLearning
7
31
2,399
Is it just me or does every article on here / substack etc. sound like it's written by the same person these days? šŸ¤”
55